高级检索
当前位置: 首页 > 详情页

Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating and RNAs in cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Tongji Univ, Shanghai Tenth Peoples Hosp, Dept Urol, Shanghai, Peoples R China [2]Tongji Univ, Urol Canc Inst, Sch Med, Shanghai, Peoples R China [3]Peking Univ, Dept Orthodont, Sch & Hosp Stomatol, Beijing, Peoples R China [4]Shanghai Jiao Tong Univ, Tongren Hosp, Dept Anesthesiol, Sch Med, Shanghai, Peoples R China [5]Capital Med Univ, Beijing Chao Yang Hosp, Dept Pathol, Beijing, Peoples R China [6]Shanghai Jiao Tong Univ, RenJi Hosp, Dept Urol, Sch Med, Shanghai, Peoples R China [7]Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
出处:
ISSN:

关键词: Key words MUC1 proteins non-coding RNAs clinical application

摘要:
Mucin 1 (MUC1) is a heterodimeric transmembrane glycoprotein that protects epithelial cells in mammals. The transmembrane C-terminal subunit (MUC1-C) plays a crucial role in oncogenesis. As an oncoprotein, MUC1-C regulates a number of proteins that are associated with tumorigenesis by interacting with oncoproteins, transcription factors, coactivators, etc., inducing proliferation, epithelial-mesenchymal transition (EMT), invasion, stemness, immune evasion, and drug resistance. Moreover, MUC1-C modulates the expression of non-coding RNAs (ncRNAs), which further regulate carcinogenesis by directly binding to specific proteins. ncRNAs can also affect MUC1 protein expression by targeting the MUC1 mRNA 3 ' untranslated region (UTR). A series of ncRNAs can modulate cancer development by regulating MUC1-C. This review focuses on the interaction of MUC1-C with proteins and ncRNAs in cancer progression. We also summarize the recent advances in immunotherapy with a focus on therapeutic approaches based on MUC1-C and nanocarrier complexes for cancer treatment.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 1 区 医学
小类 | 1 区 医学:研究与实验
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 医学:研究与实验
JCR分区:
出版当年[2020]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Tongji Univ, Shanghai Tenth Peoples Hosp, Dept Urol, Shanghai, Peoples R China [2]Tongji Univ, Urol Canc Inst, Sch Med, Shanghai, Peoples R China [*1]Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No.301 Yanchang Road,Jing'an District, Shanghai, 200072 China.
共同第一作者:
通讯作者:
通讯机构: [1]Tongji Univ, Shanghai Tenth Peoples Hosp, Dept Urol, Shanghai, Peoples R China [2]Tongji Univ, Urol Canc Inst, Sch Med, Shanghai, Peoples R China [7]Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA [*1]Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No.301 Yanchang Road,Jing'an District, Shanghai, 200072 China. [*2]Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No.301 Yanchang Road, Jing'an District, Shanghai, 200072 China. [*3]Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D830, Boston, Massachusetts, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21173 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)